Million Veterans Database Used in Large-Scale Analysis for Cardiometabolic Traits

Noting that studies linking mitochondrial DNA (mtDNA) with complex traits are often limited by small sample sizes or focused on specific phenotypes in clinically selected cohorts, researchers recently reported data from more than 600,000 participants in the Million Veteran Program (MVP) to perform a multiancestry analysis of mitochondrial DNA (mtDNA) variation and cardiometabolic phenotypes across European (EUR), African (AFR), Admixed American (AMR) and East Asian (EAS) populations.

Many Female Veterans Unaware They Can Get Menopause Symptom Care at VA

Many Female Veterans Unaware They Can Get Menopause Symptom Care at VA

Nearly half of women veterans who receive VA healthcare are at an age when menopause is most likely to occur. But, while VA offers care for menopause symptoms, like hot flashes and issues with memory, mood and sleep, an investigation by the Government Accountability Office (GAO) has found that the majority of women veterans are unaware those services exist.

More Veterans Screening Positive for Depression and PTSD

More veterans are screening positive for depression and post-traumatic stress disorder (PTSD), even as measures of suicide risk and alcohol-use disorder show modest improvement, according to a large new study of more than 3.6 million veterans receiving care through the VA.

More Treatment of High LDL-C Critical at VA to Avoid ASCVD

Pointing out that elevated serum low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), a new study decried that only one-third of veterans with ASCVD have LDL-C treated to goal despite the availability of effective drugs to lower the condition.

COVID-19 Vaccine Shows Significant Protection Against MACE in Veterans 75 or Older

Past research has demonstrated that receipt of vaccines was associated with reduced COVID-19–associated cardiovascular risk. A new study took that a step further, finding evidence of vaccine effectiveness against the broader outcome—all-cause major adverse cardiovascular events (MACEs), suggesting that “likely reflects the hidden burden of undetected SARS-CoV-2 and associated complications that are amenable to reduction by COVID-19 vaccination.”